Matthew Harrison

Q: What is Matthew Harrison's success rate?

Matthew Harrison currently has a success rate of 87.9151519700766.

Q: What is the average return of Matthew Harrison's calls?

Their stock ratings have generated an average return of 23.982076015274828.

Morgan Stanley | Healthcare

Matthew Harrison is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1405 out of 4714 analysts, they have issued 45 stock ratings with a success rate of 87.92% and an average return of 23.98%.

Matthew Harrison has a well-established track record, with 45 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 87.92% and an average return of 23.98%, underscoring their expertise and ability to identify winning opportunities for investors.

#1405

Out of 4714

Total Ratings

+87.92%

Success Rate

+23.98%

Average Return

Recent Ratings Analysis

GILD

Buy

Jul 08, 2026

Target

$166.00

Current

$135.82

Performance

0.00%

Matthew Harrison rated GILD as Overweight on Jul 08, 2026, setting a price target of 166. Shares have remained stable near 135.82, leaving the 166 target still in play.

REGN

Hold

Jul 08, 2026

Target

$730.00

Current

$662.88

Performance

0.00%

On Jul 08, 2026, REGN was given a Equal-Weight rating by Matthew Harrison, with a target price of 730. Market indecision, reflected in sideways trading near 662.88, supported the cautious call.

MRNA

Hold

Jul 08, 2026

Target

$39.00

Current

$73.80

Performance

0.00%

MRNA received a Equal-Weight rating from Matthew Harrison on Jul 08, 2026, aiming for 39. Shares remained flat at 73.8, aligning with the neutral rating.

BIIB

Hold

Jul 08, 2026

Target

$222.00

Current

$200.36

Performance

0.00%

On Jul 08, 2026, Matthew Harrison published a Equal-Weight outlook on BIIB, with a target of 222. Sideways action left the Hold view intact, with no major move since 200.36.

ARGX

Buy

Jun 24, 2026

Target

$1180.00

Current

$915.30

Performance

7.37%

Matthew Harrison on Jun 24, 2026 assigned ARGX a Overweight rating, with a price target of 1180. The Buy call aligned well with market performance, producing a gain of 7.37%.

DNLI

Buy

May 26, 2026

Target

$35.00

Current

$26.69

Performance

37.72%

On May 26, 2026, Matthew Harrison reaffirmed DNLI with a Overweight rating, targeting 35. The recommendation was supported by strong follow-through as the stock rose from 26.69 to 26.69.

LEGN

Buy

May 13, 2026

Target

$48.00

Current

$27.87

Performance

-2.79%

LEGN was rated Overweight by Matthew Harrison on May 13, 2026, with a price objective of 48. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

BMRN

Buy

May 05, 2026

Target

$119.00

Current

$59.75

Performance

12.23%

On May 05, 2026, Matthew Harrison initiated coverage on BMRN with a Overweight rating and target of 119. The stock’s climb of 12.23% since the call highlights the foresight in the rating.

INSM

Buy

Mar 30, 2026

Target

$212.00

Current

$116.53

Performance

-24.00%

Matthew Harrison issued a Overweight recommendation for INSM on Mar 30, 2026, price target set at 212. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

R

Buy

Feb 13, 2026

Target

$250.00

Current

$265.36

Performance

24.13%

On Feb 13, 2026, R was evaluated by Matthew Harrison, who gave a Positive rating and target of 250. This case illustrates how a timely bullish rating can translate into tangible gains of 24.13%.

PHVS

Buy

Dec 04, 2025

Target

$41.00

Current

$35.92

Performance

29.74%

Matthew Harrison rated PHVS as Overweight on Dec 04, 2025, setting a price target of 41. The call has proven timely, with shares rising 29.74% toward the price target of 41.

ZNTL

Hold

Nov 12, 2025

Target

$4.00

Current

$4.86

Performance

262.69%

On Nov 12, 2025, ZNTL was given a Equal-Weight rating by Matthew Harrison, with a target price of 4. The stock rallied from 4.86 to 4.86 after the Hold rating, surprising to the upside.

IOBT

Buy

Aug 12, 2025

Target

$4.00

Current

$0.01

Performance

-99.06%

IOBT received a Overweight rating from Matthew Harrison on Aug 12, 2025, aiming for 4. The rating hasn’t played out as hoped, with the stock trading 99.06% below expectations.

VRTX

Hold

Aug 05, 2025

Target

$439.00

Current

$498.43

Performance

32.92%

On Aug 05, 2025, Matthew Harrison published a Equal-Weight outlook on VRTX, with a target of 439. The Hold call missed some of the bullish momentum as shares advanced toward 439.

SRPT

Hold

Jul 29, 2025

Target

$20.00

Current

$20.21

Performance

27.67%

Matthew Harrison on Jul 29, 2025 assigned SRPT a Equal-Weight rating, with a price target of 20. Shares outperformed expectations, climbing 27.67% despite the neutral view.

TSVT

Hold

Mar 14, 2025

Target

$5.00

Current

$5.00

Performance

1.01%

On Mar 14, 2025, Matthew Harrison reaffirmed TSVT with a Equal-Weight rating, targeting 5. The neutral call matched muted market action of 1.01%.

TNYA

Buy

Mar 12, 2025

Target

$5.00

Current

$0.88

Performance

46.58%

TNYA was rated Overweight by Matthew Harrison on Mar 12, 2025, with a price objective of 5. A bullish response from the market helped close the gap of 4.12 to the target.

LYV

Buy

Feb 21, 2025

Target

$178.00

Current

$182.14

Performance

21.91%

On Feb 21, 2025, Matthew Harrison initiated coverage on LYV with a Buy rating and target of 178. The stock’s climb of 21.91% since the call highlights the foresight in the rating.

AVNT

Buy

Feb 18, 2025

Target

$56.00

Current

$35.73

Performance

-19.18%

Matthew Harrison issued a Buy recommendation for AVNT on Feb 18, 2025, price target set at 56. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

CMCSA

Buy

Jan 31, 2025

Target

$55.00

Current

$23.19

Performance

-31.11%

On Jan 31, 2025, CMCSA was evaluated by Matthew Harrison, who gave a Buy rating and target of 55. Investors saw limited payoff as shares fell short of the 55 target.

ALEC

Sell

Nov 26, 2024

Target

$3.00

Current

$1.83

Performance

-28.79%

Matthew Harrison rated ALEC as Underweight on Nov 26, 2024, setting a price target of 3. The Sell call didn’t play out, with shares rallying -28.79% to 1.83.

CNTA

Hold

Jun 21, 2024

Target

$11.00

Current

$40.50

Performance

345.05%

On Jun 21, 2024, CNTA was given a Equal-Weight rating by Matthew Harrison, with a target price of 11. The stock rallied from 40.5 to 40.5 after the Hold rating, surprising to the upside.

EDIT

Hold

May 09, 2024

Target

$7.00

Current

$3.67

Performance

-33.99%

EDIT received a Equal-Weight rating from Matthew Harrison on May 09, 2024, aiming for 7. The Hold stance proved prudent, with the market softening by 33.99%.

Frequency Asked Questions

Who is Matthew Harrison?

Matthew Harrison is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Matthew Harrison's success rate?

Matthew Harrison currently has a success rate of +87.92%.

How many ratings has Matthew Harrison issued?

Matthew Harrison has issued 45 stock ratings so far.

What is the average return of Matthew Harrison's calls?

Their stock ratings have generated an average return of +23.98%.

What is Matthew Harrison's ranking?

Matthew Harrison is ranked #1405 out of 4714 analysts.

What types of ratings does Matthew Harrison give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matthew Harrison?

You can follow Matthew Harrison by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matthew Harrison?

Their latest rating was a Buy on GILD issued on 2026-07-08.